01Sep 2021
Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia

Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia

Effective screening for term preeclampsia is provided by a combination of maternal factors with measurements of mean arterial pressure, serum placental growth factor, and serum soluble fms-like tyrosine kinase-1 at 35 to 37 weeks of gestation, with a detection rate of ≈75% at a screen-positive rate of 10%. We randomly assigned 1120 women with singleton pregnancies at high risk of term preeclampsia to receive pravastatin at a dose of 20 mg/d or placebo from 35 to 37 weeks of gestation until delivery or 41 weeks. The primary outcome was delivery with preeclampsia at any time after randomization. A total of 29 women withdrew consent during the trial. Preeclampsia occurred in 14.6% (80 of 548) of participants in the pravastatin group and in 13.6% (74 of 543) in the placebo group. Pravastatin in women at high risk of term preeclampsia did not reduce the incidence of delivery with preeclampsia.

  • #cardiology

Like

Save

Share